Navigation Links
ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences
Date:10/29/2010

EXTON, Pa., Oct. 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Oppenheimer 21st Annual Healthcare Conference at 3:55 P.M. ET on Tuesday, November 2, 2010.  The conference is being held at the Waldorf=Astoria in New York City.

Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Lazard Capital Markets 7th Annual Healthcare Conference at 1:45 P.M. ET on Wednesday, November 17, 2010.  The conference is being held at the St. Regis Hotel in New York City.

Mr. Rowland will also present at the 4th Annual Maxim Group Growth Conference at 9:30 A.M. ET on Thursday, November 18, 2010.  The conference is being held at the Grand Hyatt in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
3. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
4. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
5. ViroPharma To Participate in Two September Healthcare Investor Conferences
6. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
7. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
8. ViroPharma to Participate in Two June Healthcare Investor Conferences
9. ViroPharma To Host Investor Day
10. ViroPharma to Participate in the Cowen and Company 30th Annual Healthcare Conference
11. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ALTO, Calif. , Jan. 19, 2017   ... research, is excited to announce that the first ... Cancer Biology  (RP:CB) have been published in eLife ... this project represents the first practical evaluation of ... result in reproducible studies. Unlike other assessments of ...
(Date:1/19/2017)... Marks E-QURE , s 3 ... agreements in Israel and Argentina ... billion global market ... devices for the treatment of advanced wound care, announced today it signed a ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ("BST Device"), ...
(Date:1/19/2017)... The drug delivery technology market is projected ... 1,179.20 billion in 2016, at a CAGR of 7.2% ... diseases, increasing demand for biologics, technological advancements, and new ... this market. Whereas, self-administration & home care and rising ... opportunities for players operating in this market. On the ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... examination of how God handles sin, including how to let go of lingering guilt and ... ten long years has been waiting to release this powerful insight about forgiveness that the ... the Lord for over twenty years, and he has been preaching and teaching the Word ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: ... issue of world hunger, and shares the simple and achievable answer. “The Land of ... member of the Fairview Missionary Church in Angola, Indiana where he works with the ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells ... facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. , ... physicians and patients throughout the United States for high-quality human anti-aging and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... telemedicine solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable ... is an extension to RMT technology that delivers HD, dynamic, streaming ultrasound images ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, ... $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro ... facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital ...
Breaking Medicine News(10 mins):